Clinical trial · Interventional
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
NCT04298541CI-TRIAL-00124707withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Funding has not been solidified for the initiation of the study.
Summary
Brief summary (as posted)
The goal of this study is to propose the first direct comparison of Ga-68-DOTATATE PET/CT or PET/MR and Ga-68-DOTATOC PET/CT in patients with meningioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ga-68- DOTATATE | Drug | — | UNRESOLVED |
| Ga-68-DOTATOC | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients with Meningioma
- description
- Subjects with suspected meningioma planned for surgery who meet the inclusion and exclusion criteria.
- interventionNames
- Drug: Ga-68- DOTATATE
- Drug: Ga-68-DOTATOC
Primary outcomes (2)
- measure
- Qualitatively measure the visual appearance of target lesion to cranial blood pool using the maximum SUV ratio to compare results from Ga-68-DOTATATE and -DOTATOC PET.
- timeFrame
- Over 12 months
- description
- Compare visual appearance qualitatively using the maximum SUV ratio of target lesion to cranial blood pool (i.e. superior sagittal sinus reference region) of DOTATATE and DOTATOC PET scans in patients with meningioma. Based on our pilot clinical case series, the following reference regions will be evaluated: 1. Suspected meningioma; 2. Pituitary gland; 3. Superior sagittal sinus; 4. Brain parenchyma. Dynamic PET will be acquired and data will be analyzed including comparison of tissue-activity curves and Patlak analysis, as established by the PI in a pilot cohort. Extent of meningioma based on Ga-68-DOTATATE- and DOTATOC PET/CT will be compared to extent of disease as determined by MRI.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with clinically suspected meningioma * Patients planned for surgery - undergoing preoperative workup * No contraindications to either radiotracer Exclusion Criteria: * Age less than 18 years * Inability to lay on the scanner table for the required period of time, e.g., due to bone pain or claustrophobia.
References
Publications (0)
Data not yet available
No reference posted for this study.